IR@PKUHSC  > 北京大学第一临床医学院  > 肿瘤化疗科
学科主题临床医学
High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study
Lin, Qiang1; Wang, Jun2; Liu, Yue′ e(1); Su, Huiling1; Wang, Na1; Huang, Yuehua1; Liu, Chao-Xing3; Zhang, Ping2; Zhao, Yannan1; Chen, Kun1
关键词non-small cell lung cancer three-dimensional conformal radiotherapy vinorelbine carboplatin concomitant radiochemotherapy
刊名ONCOLOGY LETTERS
2011-07-01
DOI10.3892/ol.2011.317
2期:4页:669-674
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]THERAPY ONCOLOGY GROUP ; LEUKEMIA GROUP-B ; CONCURRENT CHEMOTHERAPY ; PHASE-III ; CISPLATIN ; CHEMORADIOTHERAPY ; TRIAL ; PNEUMONITIS ; ESCALATION ; NSCLC
英文摘要

The aim of this study was to evaluate the feasibility of high-dose 3-dimensional conformal radiotherapy (3DCRT) (70 Gy) with concomitant vinorelbine (NVB) plus carboplatin (CBP) chemotherapy in patients with non-small cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with 3-dimensional conformal radiotherapy in conventional fractionation: 2 Gy/fraction, 1 fraction/day, 5 fractions/week; total dose 70 Gy. The radiotherapy planning of every case had met the following conditions: the percentage of total lung volume receiving 20 Gy (V20) <= 30% and the percentage of total lung volume receiving 30 Gy (V30) <= 20%. Chemotherapy was commenced on the first day of radiotherapy: NVB 25 mg/m(2), day 1 and day 8, CBP at AUC of 5 mg/ml(-1).min(-1), day 8, repeated for 28 days, two concomitant cycles during radiotherapy, and not more than 4 cycles following radiotherapy. A total of 37 patients were recruited and each of them completed the entire radiation procedure. No Grade V toxicity was observed within the group. The hematological toxicity rates were: Grade III/IV neutropenia was observed in 18.9% (7/37) of cases, Grade III/IV thrombocytopenia in 8.1% (3/37) of cases, but no cases of Grade III/IV anemia were noted. For non-hematological toxicities the rates were: Grade III radiation pneumonitis, 8.1% (3/37) of cases; Grade III radiation esophagitis, 13.5% (5/37); but no cases of Grade IV/V non-hematological toxicities. High-dose 3DCRT also achieved a favorable efficacy: the complete response (CR) rate was 13.5% (5/37) and the partial response (PR) rate was 64.9% (24/37). The total response (CR+PR) rate was 78.4% (29/37). The median survival time was 12 months and the 1-year overall survival rate was 45.1%. Given that 35% of patients in the study had stage IV disease, the survival results were comparable with other similar studies. In conclusion, in our small-sample exploratory study, the high-dose regimen of 70 Gy using 3DCRT with concomitant NVB plus CBP was feasible for patients with NSCLC. Further evaluation of this regimen is ongoing in a prospective controlled phase II trial.

语种英语
WOS记录号WOS:000291503300016
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64676
专题北京大学第一临床医学院_肿瘤化疗科
作者单位1.Hebei Med Univ, Dept Oncol, Affiliated N China Petr Bur Gen Hosp, Renqiu 062552, Hebei, Peoples R China
2.Hebei Med Univ Fourth Hosp, Dept Radiat Oncol, Shijiazhuang 050011, Peoples R China
3.Beijing Univ, Hosp 1, Dept Radiat Oncol, Beijing 10034, Peoples R China
推荐引用方式
GB/T 7714
Lin, Qiang,Wang, Jun,Liu, Yue&prime,et al. High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study[J]. ONCOLOGY LETTERS,2011,2(4):669-674.
APA Lin, Qiang.,Wang, Jun.,Liu, Yue&prime.,e.,Su, Huiling.,...&Chen, Kun.(2011).High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study.ONCOLOGY LETTERS,2(4),669-674.
MLA Lin, Qiang,et al."High-dose 3-dimensional conformal radiotherapy with concomitant vinorelbine plus carboplatin in patients with non-small cell lung cancer: A feasibility study".ONCOLOGY LETTERS 2.4(2011):669-674.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Lin, Qiang]的文章
[Wang, Jun]的文章
[Liu, Yue&prime]的文章
百度学术
百度学术中相似的文章
[Lin, Qiang]的文章
[Wang, Jun]的文章
[Liu, Yue&prime]的文章
必应学术
必应学术中相似的文章
[Lin, Qiang]的文章
[Wang, Jun]的文章
[Liu, Yue&prime]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。